AGENDA AT GLANCE
AGENDA AT GLANCE
Day 1
25th September 2025
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
👤 Jaesuk Lee, Chief Scientific Officer, nSAGE, Korea
Leadership Panel Discussion: Current And Future State of The South Korea Biologics Manufacturing Market & Cell and Gene Therapy in East Asia: A Strategic Overview
Premier Ballroom A
9:00
Leadership Panel Discussion: Biologics & Advanced Therapies in South Korea & East Asia: A Strategic Overview
- Leveraging East Asia’s innovation hubs to accelerate biologics and cell & gene therapy development and commercialization.
- Overcoming region-specific supply chain and manufacturing challenges across biologics and advanced therapies.
- Unlocking opportunities for cross-border collaboration in research, clinical trials, and patient access.
Moderator:
👤 Bryan Choi, Professor, Inha University, Korea
Panellist:
👤 Ryu Kang, CSO, Vaxcell-Bio, Korea
👤 Kenji Nakamaru, VP, Head of R&D, Optieum Biotechnologies, Japan
👤 Phil Huang, Technical Director, Stemcyte, Taiwan
9:50
Advantages of Non-Glucose Carbohydrate Feeding of CHO Cell Cultures
- Impact of different cell culture fluids on the quality of recombinant proteins in CHO cells.
- Common changes made in cell culture to improve growth, viability, metabolism, and productivity.
- Why non-glucose feeds are being explored and how they can benefit cell growth and protein production.
- Results and conclusions from experiments on non-glucose feeds and their impact on CHO cell performance and protein quality.
👤 Hemasunder Reddy, Director, APAC, Pfanstiehl, Singapore
10:15
Path to Commercial Development of Cell and Gene Therapies in East Asia: Regulatory Landscape and Cross-border Collaboration.
- Recent trends in commercial development of cell and gene therapies in Asia
- Regulatory frameworks in Asia to increase patients' access
- Research infrastructure and collaboration on cell and gene therapies in Korea
👤 Bryan Choi, ISCT Asia Regional Vice-President and Professor, Inha University, South Korea
10:40
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Exhibition Hall, Ballroom B
Scaling Manufacturing for Cell & Gene Therapy: Optimizing Processes for Quality, Cost, and Speed
Premier Ballroom C
11:15
REGENECYTE, A Breakthrough of Cord Blood Stem Cell Therapy
- Expanding applications of cord blood cell beyond oncology
- The Key staring material of allogeneic cell therapy
- The new era of cell therapy
👤 Phil Huang, Technical Director, StemCyte, Taiwan
11:40
Revolution Cell Therapy Manufacturing: Advancements in Cell Culture Technology
- The role of encapsulation technology in modern cell culture techniques and understanding its applications and advantages.
- Exploring manufacturing challenges across various cell types by identifying and addressing critical gaps.
- The importance of quality, consistency and sterility in adopting innovative technologies for GMP manufacturing.
👤 Kazuchika Furuishi, Board of Director, CellFiber, Japan
12:05
The Role of scFv-CAR Optimization in Developing Functional CAR-T Therapies for Solid Tumors
- Optimized scFv-CAR enhances T-cell function & persistence
- The Eumbody System, an innovative screening platform for optimal CAR-T
- Lead product: OPTF01, anti FAPa CAR-T
👤 Kenji Nakamaru, VP, Head of R&D, Optieum Biotechnologies, Japan
12:30
Lunch Break, Exhibition Viewing & 1-1 Attendee Networking
Exhibition Hall Ballroom B
CAR-T & CAR-NK Therapies in Oncology: Case Studies from East Asia
Premier Ballroom C
1:45
Development of 5th generation CAR-T cells Platform Technology
- Clinical challenge of multifunctional CLDN18.2-targeted CAR-T therapy targeting hard-to-treat solid tumours
- Design and manufacture of CARBio's innovative 5th generation CAR vectors
- Overcoming limitations of ex-vivo CAR-T therapies: Innovative in vivo CAR-T therapies
👤 Lee Heon Ju, CEO, CarBio Therapeutics, South Korea
2:10
Clinical Development of CAR-T Cell Therapy for Hematologic Malignancy
- Phase I trial of UWC19 for R/R B-NHL
- Compassionate use of UWC19 for B cell hematologic malignancies
- Design of Phase II trial
👤 Cheng-Yi Jerry Kuo, Vice General Manager, UWELL Biopharma Co., Ltd., Taiwan
Genomic Medicine: Case Studies in Therapeutic Applications
Premier Ballroom C
2:35
Discovery and Engineering of a Novel Cas12a for Base Editing Applications
- Discovery and functional validation of a novel Cas12a ortholog
- Structure-based protein engineering using AlphaFold3 to enhance editing efficiency
- Development of a novel Cas12a-based base editor with multiplex editing capability
👤 Jaesuk Lee, Chief Scientific Officer, nSAGE, Korea
3:00
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Exhibition Hall Ballroom B
3:40
Advancing Genomic Medicine: Innovations in Polymer-Based Delivery Systems
- mRNA as next-gen modality in gene and cell therapy
- Nanaogalaxy platform of GenEdit for polymer-based mRNA delivery
- Immune modulation with mRNA for autoimmune and cancer vaccine
👤 Seokjoong Kim, Chief Strategy Officer, GenEdit, South Korea
4:05
Therapeutic Engineering of Extracellular Vesicles: From Cell Source Screening to Formulation Strategies
- Screening of diverse cell sources for EV production
- EV isolation, characterization, and functional enhancement via cell priming
- Drug formulation strategies to improve EV stability and therapeutic efficacy
👤 Chaemin Lim, Assistant Professor, College of Pharmacy & EV/Exosome Center, CHA University, South Korea
4:30
Chairman Closing Remarks
👤 Jaesuk Lee, Chief Scientific Officer, nSAGE, Korea
4:55
End of Conference Day 1
For Speaking Opportunities, Kindly Contact:
Umairoh Nurul Hafifa
Conference Producer
[email protected] | +62 856 0028 7725
Share With Your Network
